A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

NCT01650194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: enzalutamide
DRUG: abiraterone acetate
DRUG: prednisone

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]